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Inverse relationship between Alzheimer’s
disease and cancer, and other factors




Background: The AD etiology is yet not properly known. Interactions among environmental factors, multiple
susceptibility genes and aging, contribute to AD. This study investigates the factors that play role in causing AD
and how changes in cellular pathways contribute to AD.
Methods: PUBMED database, MEDLINE database and Google Scholar were searched with no date restrictions for
published articles involving cellular pathways with roles in cancers, cell survival, growth, proliferation, development,
aging, and also contributing to Alzheimer’s disease. This research explores inverse relationship between AD and
cancer, also investigates other factors behind AD using several already published research literature to find the
etiology of AD.
Results: Cancer and Alzheimer’s disease have inverse relationship in many aspects such as P53, estrogen,
neurotrophins and growth factors, growth and proliferation, cAMP, EGFR, Bcl-2, apoptosis pathways, IGF-1, HSV,
TDP-43, APOE variants, notch signals and presenilins, NCAM, TNF alpha, PI3K/AKT/MTOR pathway, telomerase, ROS,
ACE levels. AD occurs when brain neurons have weakened growth, cell survival responses, maintenance
mechanisms, weakened anti-stress responses such as Vimentin, Carbonic anhydrases, HSPs, SAPK. In cancer, these
responses are upregulated and maintained. Evolutionarily conserved responses and maintenance mechanisms such
as FOXO are impaired in AD.
Countermeasures or compensatory mechanisms by AD affected neurons such as Tau, Beta Amyloid, S100, are last
attempts for survival which may be protective for certain time, or can speed up AD in Alzheimer’s
microenvironment via C-ABL activation, GSK3, neuro-inflammation.
Conclusions: Alzheimer’s disease and Cancer have inverse relationship; many factors that are upregulated in any
cancer to sustain growth and survival are downregulated in Alzheimer’s disease contributing to neuro-
degeneration. When aged neurons or genetically susceptible neurons have weakened growth, cell survival and anti-
stress responses, age related gene expression changes, altered regulation of cell death and maintenance
mechanisms, they contribute to Alzheimer’s disease. Countermeasures by AD neurons such as Beta Amyloid
Plaques, NFTs, S100, are last attempts for survival and this provides neuroprotection for certain time and ultimately
may become pathological and speed up AD. This study may contribute in developing new potential diagnostic
tests, interventions and treatments.
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Background
The etiology of Alzheimer’s disease is yet not properly
known. Alzheimer’s disease is a neurodegenerative dis-
ease and cancers are over-proliferative. Understanding
the relationship between cancer and AD, in terms of cel-
lular pathways and molecular mechanisms will help to
understand better the pathogenesis and factors behind
Alzheimer’s disease. This study also investigates how age
related changes in growth, cell survival responses, main-
tenance mechanisms, anti-stress responses, contribute to
development and progression of Alzheimer’s disease.
In the light of scientific literature, it points that changes
and appearance of tau, beta amyloid, S100, C-ABL, GSK3,
neuro-inflammation in neurotoxic environment of AD
may just be the countermeasures by AD affected neurons
as last attempts for survival. This research paper also
points to possible mechanisms and pathways that may be
playing role or contributing to Alzheimer’s disease patho-
genesis. But these possible mechanisms and pathways
need to be further investigated.
It is already known that in severe cases of AD amyloid
plaques may be undetectable, but may be present in
brains of those lacking dementia, and NFTs have been
found to be linked to longevity of neuron. Other factors
may be causing bulk of neurodegeneration in this dis-
ease, not the NFTs. There is exponential rise with age in
the occurrence of both AD and cancer. Epidemiological
studies have shown a reciprocal association between
Alzheimer’s disease and cancer; elderly with AD demen-
tia have a decreased risk of cancer and vice versa [1, 2].
It is already known that among Huntington disease pa-
tients; there is lower occurrence of cancer [3]. This
makes it more essential to investigate the inverse rela-
tionship between Cancer and AD.
This study may also possibly contribute to the devel-
opment of new diagnostic tools and new treatments for
Alzheimer’s disease. The circumstances which lead to
the development of AD remain unclear yet and this
study also tries to investigate them. It also highlights the
cellular and molecular pathways that are involved in AD
and Cancer, and also simultaneously pointing to their re-
lationships in both the disease processes. It also suggests
some hypothesis in the light of scientific literature and
also highlights the changes occurring at cellular and mo-
lecular level that contribute to development of AD.
Methods
PUBMED database, MEDLINE database, Google Scholar
and other online Journals such as BMC, Neurology
today and others were searched with no date restrictions
for published articles using keywords P53, estrogen, neu-
rotrophins, growth factors, growth and proliferation,
cAMP, EGFR, Bcl-2, apoptosis pathways, IGF-1, HSV,
TDP-43, APOE, notch signaling, presenilins, NCAM,
TNF alpha, PI3K/AKT/MTOR pathway, telomerase,
ROS, ACE levels, vimentin, carbonic anhydrases, HSPs,
SAPK, Carnosine, neuro-protection, antineoplastic,
FOXO, Tau, Beta Amyloid, S100, C-ABL activation,
GSK3, neuro-inflammation. All these keywords were
searched with terms such as cancer, Alzheimer’s disease,
and those mentioned in eligibility criteria. For example,
“IGF-1 and Alzheimer’s disease”, “IGF-1 and Cancer”.
Some additional articles of interest were selected from
reference lists of included articles.
Only those articles were eligible to be included which
involved cellular pathways having roles in cancers, devel-
opment, aging, cell survival, growth and proliferation,
and also contribute to Alzheimer’s disease. Screening of
the literature was also done on the same basis. Literature
search began in January 2013 and ended in January
2016. The prime focus of the literature search was to
screen the literature on the basis of eligibility criteria.
Publications only in English were used and there was
not any limitation on date of publication. Data extrac-
tion was based on expression of factors common in cel-
lular pathways having roles in cancers, cell survival,
growth, proliferation, development and aging. And also
contribute to Alzheimer’s disease. If many separate stud-
ies were present with similar conclusions, then only
those were selected to be included which were most
relevant to the objectives of the study and research ques-
tion. No unpublished study was used or included. This
manuscript adheres to PRISMA guidelines. This re-
search study finds evidence from already published re-
search literature to find factors and changes that lead to
the development of Alzheimer’s disease and finds the in-
verse relationship between Cancer and Alzheimer’s
disease.
Results
A total of 1824 articles were identified using database
searching, 1590 were recorded after duplicates removal.
One thousand three hundred sixty-six were excluded
after screening of title/abstract, 119 were finally ex-
cluded (because when many separate articles were
present with similar conclusions, then only those were
selected to be included which were most relevant to the
objectives of the study and research question), 4 were
excluded during data extraction. Finally 101 articles were
included (because they involved cellular pathways having
roles in cancers, development, aging, cell survival,
growth, proliferation and also contributing to
Alzheimer’s disease).
Inverse relationship between cancer and Alzheimer’s
disease
There is inverse relationship between Cancer and
Alzheimer’s disease in aspects such as P53 is upregulated
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in Alzheimer’s disease and down-regulated in Cancer, es-
trogen is neuro-protective but increases the risk of
cancers, neurotrophins and growth factors are neuropro-
tective but are also involved in tumor growth progres-
sion, age related decline in proliferation of new cells
contribute to AD development while pathways and
mechanisms that contribute to growth and proliferation
delays AD, cAMP provides survival signal for neurons and
is also involved in tumor progression, EGFR is overex-
pressed in cancer but EGFR is not found in Alzheimer’s
plaques, Bcl-2 downregulated in Alzheimer’s disease but is
overexpressed in cancer, apoptosis pathways are upregu-
lated in Alzheimer’s disease but downregulated in cancer,
IGF-1 is decreased in Alzheimer’s disease but increased in
cancer, dysfunctional proliferation of neurons occurs in
Alzheimer’s but in cancer there is over-proliferation of
cells, HSV is oncolytic but contributes to Alzheimer’s dis-
ease development, TDP-43 role in Alzheimer’s disease and
cancer and its relation to IGF signifies the inverse relation-
ship between cancer and AD, Alzheimer’s risk decreases
from apoE4 to E3 to E2 but growth and survival improves
respectively, pathophysiologic notch signals potentially
contribute to cancer but presenilins are also involved in
notch signalling and they mutate in familial early-onset
AD, neural cell adhesion molecule decrease in AD but
stain positive in neoplasia, Tumor Necrosis Factor-α has
anti-cancer properties and its overexpression causes
neurotoxic environment but secondary signal is necessary
for the induction of neuronal death, PI3K/AKT/MTOR
pathway is neuroprotective but in many cancers this path-
way is overactive, telomerase in cancer cells prevents
senescence related death and AD is associated with accel-
erated neuronal death, ROS when excessive slows cancer
proliferation and ROS are increased in Alzheimer’s
disease, ACE levels are decreased in Cancer but are
elevated in Alzheimer’s disease.
Epidemiological studies have also pointed towards the
inverse relationship between Alzheimer’s disease and
Cancer [1, 2]. All those factors that contribute to growth
and proliferation are increased in cancers but decreased
in Alzheimer’s disease. This simply does not mean that
every cellular or molecular pathway should have inverse
relationship; there are so many pathways that are com-
mon and even operate similarly in many cell types, and
are not altered by the disease processes.
Apoptosis pathways including P53 are upregulated in
Alzheimer’s disease and down-regulated in cancer
P53 downregulation is the foundation of most tumors.
Inactivation of TP53 confers a predisposition to cancer,
while Alzheimer’s disease (AD) leads to apoptosis induc-
tion by the p53 pathway. Massive neuronal death repre-
sents important neuropathological hallmarks of AD. P53
can initiate apoptosis if DNA damage proves to be
irreparable. P53 activation leads to cell cycle arrest via
p21 and same p21 stops cells from dividing after being
exposed to damaging agents. Upregulation of p21 results
in aging and cell cycle arrest [4]. It is already known that
deletion of p53/p21 in mouse models improves aging
phenotypes and extends the life span but increases the
risk of cancer.
Amyloid Precursor Protein (APP) mediates partly p53
expression, binding of Aβ especially to promoter of p53
increases transcription of p53, and tau phosphorylation
is indirectly stimulated by p53 [5]. Complete deletion of
Tp53 occurs in Li-Fraumeni syndrome, lifetime cancer
risk increases to 100% by age 70 years in these patients
[6]. This signifies the inverse relationship between AD
and Cancer, as upregulation of P53 is present in AD and
its downregulation or deletion is involved in cancers.
In human neuroblastoma cells, Aβ42 has been found
to lower the expression of the X-linked inhibitor of
apoptosis (XIAP), and overexpression of XIAP reduces
the vulnerability to oxidative stress caused by Aβ42 [7].
It is important to note that apoptosis is upregulated in
Alzheimer’s disease and down regulated in Cancer cells.
Estrogen is neuro-protective but increases the risk of can-
cers; this signifies the inverse relationship between AD and
cancer
Estrogen is both neurotrophic and neuroprotective. It
even protects isolated neurons in vitro from hypoglycemic
and ischemic injuries, oxidative stress, and from damage
by Aβ42; which is implicated in the AD pathogenesis.
Nerve growth factors promote neuronal viability, repair
and growth of damaged neurons, and dendritic branching.
Estrogen also increases their production.
An imbalance occurs in AD between neuronal injury
and repair. The role of Estrogen in reducing the risk of
AD is well established [8]. It is already known estrogen
increases the risk of Cancers i.e. ovarian, endometrial,
breast [9].
Neurotrophins and growth factors are neuroprotective and
are also involved in tumor growth progression
NGF is also involved in regulating tumour growth and
progression of cancers including lung, medullar thyroid
carcinoma, prostatic, breast and pancreatic carcinomas.
Interactions of neurotrophic factors and glutamate are
also involved in regulating developmental and adult neu-
roplasticity. For example, production of brain-derived
neurotrophic factor (BDNF) is stimulated by glutamate,
and BDNF modifies glutamate sensitivity of neurons,
neuronal plasticity, and Ca2+ homeostasis. Neurotrophic
factors also change the expression of glutamate receptor
subunits and Ca2+-regulating proteins, and also induce
the production of anti-apoptotic Bcl-2 family members,
antioxidant enzymes and energy-regulating proteins.
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Oxidative and metabolic stress activate glutamate recep-
tors in excess, may contribute to neuro-degeneration
and dysfunction in stroke psychiatric disorders and
Alzheimer’s disease [10].
Enhancement of environmental factors such as exer-
cise, neurotrophic factor signaling, antidepressants, diet-
ary energy restriction have the potential to optimize
glutamatergic signaling and protect against neurological
disorders. Physiologically BDNF is involved in neuronal
growth and survival. In areas vital to learning, memory,
and higher thinking such as hippocampus, cerebral cor-
tex, and basal forebrain; BDNF actively plays its role. It
is significant for long term memory and neurogenesis
[11, 12].
Current knowledge suggests strongly that epidermal
growth factor (EGF) and the neurotrophins – nerve
growth factor (NGF), brain derived nerve growth factor
(BDNF), neurotrophin-3 (NT-3) and neurotrophin 4/5
(NT-4/5), as well as their tyrosine kinase receptors –
epidermal growth factor receptor (EGFR) and members
of the trk family (trk A, trk b and trk c) play a significant
role in stromal–epithelial interactions during Prostate
Cancer pathogenesis [13].
Expression of BDNF also occurs in cancers such as
colon cancer, and alters the behavior of cancer cells at
cellular level. It also reduces the apoptosis of colon can-
cer cells [14]. There is significant role of inflammation in
AD pathogenesis. In AD, there is down-regulation of
BDNF and other neurotrophins. There are lower levels
of BDNF in the brain tissues of people with Alzheimer’s
disease [15], and it has already been known that BDNF
is anti-apoptotic, also plays role in progression of cancer.
Age related decline in proliferation of new cells contribute
to AD development, while pathways and mechanisms that
contribute to growth and proliferation delays AD
Exercise enhances the size of hippocampus, and im-
proves memory function. BDNF plays a significant role
in this process [16]. Physical activity reduces risk of
Alzheimer’s disease. There are significant gene expres-
sion changes in exercising and non-exercising muscles,
because of exercise [17]. Exercise makes changes in
genome at epigenetic level — particularly in genes linked
to fat storage and a high risk of developing diabetes or
obesity [18]. In subgranular zone of hippocampal den-
tate gyrus, generation of new neurons continues
throughout lifetime. Neurogenesis lowers with aging,
and this decrease also contributes to mild cognitive im-
pairment. Neurodegenerative diseases are associated
with decreased neurogenesis, and increasing hippocam-
pal neurogenesis with methods like environment enrich-
ment, exercise, diet restriction, slows AD progression.
Exercise increases memory function and plasticity
of hippocampus. With increasing age, hippocampal
neurogenesis is decreased and exercise attenuates
age-related reduction in hippocampal generation of
neurons [19].
TGF beta: Anti- proliferative physiologically—increased
levels in AD but in cancers its normal anti-proliferative
functioning is disrupted and is redirected to contribute
to tumorigenesis
In normal cells, TGF-β halts cell cycle at the G1 stage to
stop proliferation and induces cell to differentiate or go
towards apoptosis. In many cancer cells, TGF-β is mu-
tated and its normal functioning is impaired. It contrib-
utes to make cancer more aggressive via causing
immunosuppression and angiogenesis, also influences
surrounding stromal cells, immune cells, endothelial and
smooth-muscle cells [20]. TGF-β also converts effector
T-cells into suppressor T-cells, which halt the inflamma-
tory reaction. Increased levels of TGF-β are found in the
cerebrospinal fluid and blood of AD patients as com-
pared to control subjects [21], suggesting a possible role
in the neurodegenerative processes leading to Alzhei-
mer’s disease development. The role TGF beta plays in
AD and cancer signifies the inverse relationship between
these diseases.
cAMP provides survival signal for neurons and also
involved in tumor progression
Cyclic AMP (cAMP) is such a powerful survival signal
for neurons, that even the survival of in vitro neurons is
greatly enhanced by increased intracellular cAMP levels.
cAMP enhances neuronal survival, but survival is signifi-
cantly enhanced when cAMP is in combination of mul-
tiple peptide trophic factors [22]. Cyclic AMP elevation
sufficiently enhances the neuronal survival even in vitro.
Many peptide trophic factors, including brain-derived
neurotrophic factor (BDNF), ciliary neurotrophic factor
(CNTF), fibroblast growth factor (FGF), glial-derived
neurotrophic factor (GDNF), and hepatocyte growth fac-
tor (HGF), promote the short-term survival of highly
purified embryonic spinal motor neurons (SMNs) in cul-
ture [23]. Cyclic AMP is already known to have role in
tumor progression. Aberrant activation of cAMP-
controlled genes and deregulation of cAMP pathways is
linked to the growth of some cancers [24].
EGFR is involved in growth, proliferation and survival of
cells and it is overexpressed in cancer but becomes deficient
in AD. This also signifies the inverse relationship between
Alzheimer’s disease and cancer
Several cancers, including glioblastoma multiforme, lung
cancer and anal cancers, are associated with overexpres-
sion of epidermal growth factor receptor (EGFR). In can-
cers of epithelial origin, EGFR overexpression plays
important role in their pathogenesis [25]. But EGFR is
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absent in central core of AD neuritic plaques [26]. EGF;
a mitogen for neural stem and progenitor cells, also
plays role in hippocampal neurogenesis and cognitive
function’s improvement [27].
Bcl-2 downregulated in Alzheimer’s disease but
overexpressed in cancer
BCL-2 overexpression occurs in many cancer types and
is associated with chemo-resistance and radio-resistance.
Increased levels of Bcl – 2 lower the propensity of can-
cer cells to initiate apoptosis. Expression of Bcl-2 and
other oncogenes is increased in cancer; this contributes
to cancer cell survival. But in AD, there is down-
regulation of Bcl-2 [28]. Bcl-2 overexpression has already
been shown to provide protection against beta amyloid
induced cell death, and this effect is possibly related to
decrease in beta amyloid induced activation of p38
MAPK and NF-κB [29].
IGF-1 is decreased in Alzheimer’s disease but increased in
cancer, signifying the inverse relationship between AD and
cancer
Lack of Insulin or Insulin like Growth factors potentiate
the AD. High IGF levels are present in cancers. Congeni-
tal deficiencies in IGF-1 protects against the develop-
ment of cancer [30]. In diabetic mouse models, aging
has been found to cause impairment of the respiratory
chain and to lower efficiency of oxidative phosphoryl-
ation and also the mitochondrial capacity to accumulate
Ca2+. Beta amyloid’s presence accelerates the age related
mitochondrial effects. When in the presence of Aβ40,
brain mitochondria were isolated from diabetic rats; in-
creased levels of H2O2 were observed. But insulin and
coenzyme Q10 (CoQ10) treatments prevented these
pathological effects [31].
IGF – 1 plays significant role in normal physiological
mechanisms and also in disease states, including cancer.
IGF axis inhibits cell death and promotes cell prolifera-
tion, it also is involved in neural development including
neurogenesis, myelination, synaptogenesis, and dendritic
branching and neuroprotection after neuronal damage.
Higher IQ has also been associated with increased serum
levels of IGF-I in children. IGF-2 is also significant for
function and development of organs such as the liver,
kidney and brain. Risk of AD dementia is also associated
with lower serum levels of IGF-1, and higher levels of
IGF – 1 are associated with greater brain volumes and
lower risk of dementia and stroke. Higher IGF-1 levels
may protect against neurodegeneration [32].
It is already known that diabetes especially type 2, is
associated with increased risk of developing AD and
other dementias [33]. This signifies the inverse relation-
ship between Alzheimer’s disease and cancer, as IGF
contributes to cell proliferation and halts cell death. Its
levels are increased in cancer and plays role in carcino-
genesis but IGF levels are decreased in Alzheimer’s dis-
ease and there is accelerated neuronal death. Aging is a
major risk factor for AD as expression of COX subunits
II and IV is decreased during aging and such age-related
changes are more marked in AD [34].
Leigh syndrome includes the loss of mental function
but not with AD specific symptoms, though there is
cytochrome c oxidase deficiency. This potentially sug-
gests that COX reduction is a consequence of the dis-
ease not the key causative factor.
Dysfunctional proliferation of neurons occurs in
Alzheimer’s, and Cancer is over-proliferative disease
In Alzheimer’s disease, proliferation of neurons becomes
dysfunctional, despite some neurogenesis there is overall
great neuronal loss. But in cancer, the cells gain the cap-
acity to over-proliferate and they also regulate the
microenvironment if favor of their survival. This signifies
the inverse relationship between Alzheimer’s disease and
cancer.
Morphogens play significant role in embryonic devel-
opment of nervous system, including Wnts, Notch, Shh,
and BMPs. They are conserved and continue to play role
as niche signals for adult neural stem cells to regulate
maintenance, activation, and fate choice of NSCs.
Neurogenesis is also regulated by various neurotrophins,
cytokines, hormones, neurotransmitter systems and
growth factors. Transcription factors, miRNAs, epigen-
etic factors and cell-cycle regulators provide adult NSCs
with the potential to differentiate, proliferate and survive
as newborn neurons. Newborn neurons differ substan-
tially from their older, neighboring counterparts in terms
of electrophysiological properties. They show increased
plasticity. ApoE, PS1, APP and its metabolites, can
modulate adult hippocampal neurogenesis, these
molecular players known to contribute to AD pathogen-
esis. Risk of AD may be exacerbated by Dysfunctional
neurogenesis resulting from early subtle disease manifes-
tations, whereas increased neurogenesis represent an
endogenous brain repair mechanism and possibly be
compensatory response. NFTs, beta amyloid plaques and
massive neuronal death are significant neuropathological
hallmarks of AD. These pathologies deeply harm hippo-
campus among other specific vulnerable areas in brain.
Adult hippocampal neurogenesis play role in improve-
ment of pattern separation and spatial memory. Aging de-
creases neurogenesis, and this in turn contributes to AD.
Neurogenesis has the potential to delay or halt AD-
linked cognitive decline. But it is altered at the very early
stage of AD progression, even before appearance of
neuronal loss, amyloid deposition and inflammation.
Dysfunctional neurogenesis is a significant part of AD
pathology. Endogenous neurogenesis stimulation via
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environmental stimuli, physical activity, trophic factors,
cytokines, and drugs may promote the recovery and
regeneration process [35].
AD-related inflammation may explain the increase in
hippocampal neurogenesis. Inflammatory factors
changes patterns of proliferation or survival of new cells,
and in turn may affect neurogenesis. Transforming
growth factor beta 1 (TGFβ-1), a strong inflammatory
factor present in AD enhances neurogenesis [36]. Role
of immune system in neurogenesis is complex and
depends on multiple factors [37].
Role of neurotransmitters as growth regulatory signals
are well established, they have neuroprotective effects
against dementia. As it’s already known when many AD
patients died they had lower than normal levels of
Acetylcholine. Estrogen’s neuroprotective role against
AD is also well established.
HSV is oncolytic and also contributes to Alzheimer’s disease
development, this signifies the inverse relationship between
cancer and AD
HSV 1, mediates selective oncolysis of gliomas. Genes
related to mammalian DNA damage and growth arrest;
GADD3, are very homologous to C-terminal 70-amino
acids of HSV 1. Cellular proteins interact to halt the
protein synthesis by double-stranded RNA-activated
protein kinase [38]. Within Alzheimer’s disease amyloid
plaques, HSV 1 DNA has already been found [39].
When cultured neurons and glial cells are infected with
HSV 1, it leads to elevated levels of beta-amyloid 1–40
and 1–42 within the cells, but there is decrease in amyloid
precursor protein (APP) levels. Even after HSV 1 infec-
tion, beta amyloid plaques appear in mouse brain [40].
Role of HSV 1 is oncolytic and it also has the capacity
to contribute to Alzheimer’s disease pathogenesis as the
pathways that work against cell proliferation and sur-
vival, are involved in AD development. This signifies the
inverse relationship between Alzheimer’s disease and
cancer.
TDP-43 role in Alzheimer’s disease and cancer and its
relation to IGF, signifying the inverse relationship between
cancer and AD
Abnormal TDP - 43 causes genomic instability and in-
creased apoptosis, and this also plays role in AD devel-
opment. Deficiency of IGF potentiates the damage by
this pathway. Normally TDP 43 regulates CDK 6. CDK 6
is upregulated in Cancer and down-regulated in AD. Ab-
normal TDP - 43 increases in AD and loss of TDP-43
contributes to cancer via upregulation of CDK6.
When TDP-43 becomes abnormal, the severity of clin-
ical deficits increases and there is greater atrophy in
brain, particularly in hippocampal region [41]. Levels of
Cdk6 increase 10-fol when TDP-43 is absent.
Physiologically, Cdk6 plays role in determining differen-
tiation of several cell types. But elevated levels of Cdk6
expression are associated with several tumors [42].
There is strong association of abnormal TDP- 43 with
AD related cognitive impairment [43].
Insulin and IGF-1 signaling is also considered to have
roles in contributing to biological aging in several organ-
isms, and it is already known that misfolding of proteins
contributes to age- related degeneration of neurons as-
sociated with TDP-43, and a significant decrease/defi-
ciency in IGF-1 and insulin levels has the potential to
lower the neurotoxicity of abnormal TDP-43 aggregation
[44]. Beta amyloid related oxidative stress and impair-
ment in mitochondrial OXPHOS efficiency can poten-
tially be prevented by IGF and coenzyme Q10 related
treatments [31]. It is already known that IGF levels are
increased in cancer and decreased in AD.
It is the biological aging mechanisms that are ultim-
ately contributing to the pathogenesis of AD and cancer,
and even the risk of both also increases significantly with
increasing age.
Alzheimer’s risk decreases from apoE4 to E3 to E2 but
growth and survival improves from E4 to E3 to E2
It is already known APOE influences AD risk [45], but
the underlying mechanisms are not yet determined. The
pathways and mechanisms that play roles in growth, sur-
vival, and oncogenesis, when downregulated or not func-
tioning properly; they contribute to development of
Alzheimer’s disease. This finding has been elaborated in
terms of ApoE variants.
It is important to note that APOE4 has highest risk for
AD, and apoE4 also lowers neurite outgrowth. APOE3 is
very common but poses less risk compared to E4, and
E3 also inhibits the proliferation of tumor cells among
other cell types. But apoE3 increases neurite outgrowth
mostly, but not always.
E2: This variant is rare and least dangerous. In colon
cancer this apoE contributes to cell growth. E2 and E4
variants have opposite actions, and this further supports
the role of APOE in AD pathogenesis. Alzheimer’s risk
decreases from apoE4 to E3 to E2 but growth and sur-
vival improves respectively. Genotype APOE2 and E3
are associated with lowest risk of AD [46].
APOE plays its role in repair mechanisms after tissue
injury. It also modulates cell differentiation, growth and
is also involved in immune regulation. APOE is involved
in neuroprotection, neurite outgrowth, neural develop-
ment and regeneration. It plays role in remodeling after
neuronal injury, to restore neuronal function [47]. But
APOE4 is unable to do these functions properly.
Expression of APOE has already repeatedly been de-
tected in serous carcinomas of ovary. ApoE-specific
siRNA when used to halt ApoE expression, it arrested
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the cell cycle and led to apoptosis in an ovarian cancer
cell line. APOE plays role in proliferation and survival of
apoE-expressing ovarian cancer cells [48], and APOE is
also associated with AD; a neurodegenerative disease.
APOE also contributes to maintenance and prolifera-
tion of some adult neural stem cells [49]. APOE4 variant
is associated with highly increased risk of AD. APOE3 is
more common and has lesser AD risk. E2 variant is as-
sociated with the least AD risk. It is important to note
that inheritance of APOE4 increases the risk of AD de-
velopment, only the risk but not the disease itself, as not
everyone with this allele develops AD. This most likely
shows APOE4 itself is not an exact causative factor but
it may be an associated or contributing factor. Malignant
and normal human intestine, both express APOE. Ex-
pression of APOE also impacts cultured human colonic
adenocarcinoma cells.
Macrophage-derived Apo-E has the capability to regu-
late integrity of epithelial cells and this way also contrib-
utes to growth of cells [50]. Apolipoprotein E3: It is
involved in inhibiting the proliferation of tumor cells
and endothelial cells among other cell types in a dose
and time dependent manner. E3 can strongly inhibit the
proliferation of many cell types. Metastasis, angiogenesis
and tumor cell growth may effectively be modulated by
APOE3 [51].
Role of APOE4 in pathogenesis of AD, MS and in redu-
cing hippocampal volume is already well known. We
already know that all these diseases are associated with de-
struction of neurons. Poor prognosis in patients of trau-
matic brain injury is also related to APOE4 genotype.
It is already known that brain needs regeneration and
repair to counter TBI, and the presence of APOE4
linked to poor outcome, this also points to its anti-
proliferative effects. APOE4 in female carriers has been
shown to contribute to accelerated telomere shortening
and biological aging, hormone replacement therapy halts
this accelerated aging [52].
While in cancer there is increased activity of Telomerase
causing elongation of telomeres in cancer cells. This also
signifies the link between hormones and AD as those
APOE4 carriers who continued to use hormone replace-
ment therapy; did not show signs of accelerated aging.
Reduced levels of androgens also potentially increase the
risk of AD.
APOE4 contributes to reduced neurite outgrowth:
APOE isoforms regulate neuronal ability to regulate re-
model, and APOE4 allele impairs with ability in AD pa-
tients. E4 variant even dominates its effects when
present with E3. It is important to note that E3 variant
is associated with increased growth of neurite [53].
The APOE4 and APOE2 variants have opposite ac-
tions, and their roles in growth and survival also signify
the inverse relationship between cancer and AD.
Pathophysiologic notch signals potentially contribute to
cancer but presenilins are also involved in notch signalling
and mutated PS is involved in familial early-onset AD
Presenilins are also implicated in the processing of notch,
an important developmental protein. Familial early-onset
AD is associated with mutated Presenilin 1 (PS1) and Pre-
senilin 2 (PS2) genes. Normal PS 1 and PS 2 are also in-
volved in intramembranous cleavage of Notch. Notch
signaling pathway is very significant for multiple cell dif-
ferentiation processes, gene regulation and cell to cell
communication. Its role in neuronal function and devel-
opment is already well established. When this pathway is
inhibited, this results in anti-proliferative effects. Notch
signaling is also involved in CNS plasticity. Mutations in
notch1 have been shown to result in spatial learning and
memory deficits. Such similar also appear in experiments
involving PS 1 and PS 2, specifically when Presenilins are
deleted at 3 weeks post-birth, this causes dysfunction and
degeneration of neurons gradually, also causes deficits in
learning and memory. Notch signaling plays a significant
role in developmental pathways and also play roles in
cancers [54].
Cytokines, hormones, and neurotransmitters, morpho-
gens, proteoglycans, and growth factors are involved in
influencing the proliferation and survival of neural stem
cells, and they are called Neural Stem Cell Survival fac-
tors. Notch signaling diversely effects cellular prolifera-
tion, survival, and differentiation, it also plays an
important role in normal developmental processes of
many cell types. When this signaling becomes patho-
physiologic, it then also contributes to malignant trans-
formations [55, 56].
This signifies the inverse relationship between cancer
and AD, as mutant PS is involved in AD and normal PS
itself is involved in processing of Notch, the pathophysi-
ology of which is implicated in cancer.
Neural cell adhesion molecule (NCAM), also called CD56,
decrease in AD but stain positive in neoplasia
APOE4 genotype is associated with low NCAM levels.
AD is also associated with low levels of BDNF in tem-
poral and frontal brain regions [57]. NCAM is also in-
volved in inducing neurite outgrowth via FGFR and also
acts on other signaling pathways.
CD56 (NCAM) immunohistochemistry is also used by
pathologists to identify specific tumors such as pheo-
chromocytoma, paraganglioma, T cell/ natural killer
lymphoma, myeloid leukemia, myeloma, neuroendocrine
tumors, Wilms’ tumor, neuroblastoma, pancreatic acinar
cell carcinoma, Ewing’s Sarcoma and small cell carcin-
oma of lung.
It is important to note that normal cells also having
positive staining for CD56 include neuroendocrine tis-
sues, cerebellum, brain, NK cells and activated T cells.
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Beta-amyloid even harms NCAM2 and there are de-
creased levels of NCAM2 in hippocampus of AD
patients [58].
Tumor Necrosis Factor-α overexpression causes neurotoxic
environment but neuronal death occurs when secondary
signal is also present
TNF alpha negatively impacts neurotrophins and pro-
motes apoptosis. The inverse relationship between
Cancer and Alzheimer’s disease in terms of neurotro-
phins and apoptosis has already been mentioned in this
paper. Neurotoxic microenvironment and secondary sig-
nals play significant roles in causing TNF alpha to be-
come harmful for brain cells. Dentate gyrus has been
shown to have accelerated development when expression
of TNF-α is absent, and this has been correlated to in-
creased levels of nerve growth factor. Though, when
TNF-α expression was absent, this absence impacted the
branching of dendrites in hippocampal region. TNF-α
over-expression has been shown to; decrease branching
of dendrites, antagonize the production of NGF and
lower neurotrophin levels in hippocampal region. TNF-α
knock-out mice have also shown signs of increased
memory function in hippocampus. TNF-α overexpres-
sion is associated with impairment in memory and
learning function in hippocampus.
TNF-α signaling also has the capacity to negatively im-
pact neuronal function. Pro-inflammatory cytokines
lower long-term potentiation, and in turn also impair
memory and learning. In AD, when amyloid plaques
begin to accumulate, memory and learning deficits start
becoming clear, and it is also the same time when TNF-
α involvement occurs.
It is important to note that when TNF alpha levels are
experimentally increased or it is overexpressed, it pro-
duces neurotoxic environment. TNF-α exposure has
been suggested to be involved in beta amyloid plaques
production.
TNF- alpha inhibition has also shown to improve
cognitive status of AD patients [59]. TNF alpha and
Apoptosis response: Many studies have also reported
that besides TNF- alpha, an appropriate cellular environ-
ment or a secondary signal should also be present to ini-
tiate apoptosis, and when TNF – alpha is present alone,
it has the potential to prevent induction of cell death
after cellular insults. Degenerating environments and
oxidative stress likely sensitize brain cells to inflamma-
tion driven apoptosis. Absence of TNF – alpha expres-
sion has been to enhance neuronal death when cerebral
ischemia was induced in mice models. TNF alpha when
expressed alone, it provides protection against neurotox-
icity and even against beta amyloid plaques. Impact of
TNF-alpha on neuronal viability is dependent on the
presence or absence of secondary signals, which may
arise from endogenous stimuli or exogenous situational
stimuli [59].
PI3K/AKT/MTOR pathway is neuroprotective and in many
cancers this pathway is overactive, signifying the inverse
relationship between Alzheimer’s disease and cancer
The process of phosphorylation of specific proteins by
activated AKT is involved in angiogenesis, cell cycling,
metabolism, and cell survival, and it provides neuropro-
tection. AKT significantly regulates cell death and sur-
vival. The evolutionary conserved mTOR is a kinase that
is involved in controlling the translation process of sev-
eral mRNA transcripts having involvement in prolifera-
tion and growth of cell. Activated PI3K induces the
activation of AKT [60]. PI3K/AKT/MTOR pathway is an
intracellular signaling pathway that is neuroprotective.
This pathway decreases apoptosis and promotes prolifer-
ation, there is over activation of this pathway in many
cancers. The role of this pathway in cancer appears to
be crucial [61].
Telomerase in cancer cells prevents senescence related
death and AD is associated with accelerated neuronal
death
In cancer cells, the function of telomeres is overcome by
overexpression of an enzyme known as telomerase.
Telomerase replaces the portion of the telomeres that is
lost with each cell division, thereby avoiding senescence
and permitting an infinite number of cell doublings.
Telomerase is a target for antineoplastic drug develop-
ment. It’s important to note that cancer cells have the
ability to counter aging related death of their cells, by
overexpression of an enzyme known as telomerase [62].
Alzheimer’s disease is associated with accelerated
neuronal death. Shortening of telomere increases the in-
stability of genome and formation of tumors, this has
been shown in mouse models. This signifies the role of
telomere length and activity of telomerase in the main-
tenance of genomic integrity. Telomere dysfunction con-
tributes to genome instability in human cancer. But
neoplastic cells have increased telomerase activity. There
is huge overlap between genes changing expression with
AD and those with age, direction of these changes is
most often same. Aging related changes in gene expres-
sion may actually be increasing the risk of AD develop-
ment [63].
In AD, epigenetic modifications impact both chroma-
tin and DNA at molecular level, including cofactors and
transcription factors. Transcription in neurons is regu-
lated by amyloid intracellular domain (AICD) and
Amyloid precursor protein (APP).
Role of chromatin remodeling and epigenetics in
development of neurodegenerative diseases has emerged
to be very significant. Changes in machinery of
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epigenome alter methylation of DNA and acetylation of
histone, and this ultimately alters the gene transcription
of APP and other genes involved in AD [64, 65].
Spontaneous tumors have deep evolutionary roots.
Multi-cellular life and cancer, history of both is very old.
Even in a primitive animal hydra, a primordial cancer
has been discovered. There are great alterations in tran-
scriptome of hydra tumors. These alterations mimic
expression changes in vertebrate cancer [66].
Telomerase in cancer cells prevents senescence related
death and AD is associated with increased neuronal
death, this signifies the inverse relationship between
Alzheimer’s disease and cancer. It may be hypothesized
here that both disease processes are somewhat inter-
linked, as the major prevalence of both cancer and AD
increases in people older than 55. In progeria, aging
occurs several times faster than normal. If alone aging
would have been the only factor predisposing to cancer
and AD, then at least any of them would have been af-
fecting progeria kids, but progeria patients show no neu-
rodegeneration or cancer predisposition. But this needs
to be further investigated.
Reactive oxygen species when excessive slows cancer
proliferation and ROS are increased in Alzheimer’s disease
Dysfunction of mitochondria and oxidative stress con-
tributes to the pathogenesis of Alzheimer’s disease. With
increasing age, ROS increases in brain and this accumu-
lation of ROS accelerates with AD. All this might be due
to aging and AD related neuronal damage [67]. Once a
cell has become cancerous then excessive stress by ROS
slows proliferation and threatens survival [68].
ACE levels are decreased in cancer but are elevated in
Alzheimer’s disease, signifying the inverse relationship to
both AD and cancer
Surface of many cell types, such as macrophages, den-
dritic, endothelial, neuro-epithelial, epithelial cells ex-
press constitutively ACE (CD 143) as a membrane
bound protein. Most of the cancer patients tested pre-
sented with the ACE mean value for all patients being
70% of the standard value [69]. In AD, activity and levels
of ACE are generally increased in the cerebral cortex
[70]. The role of ACE (CD 143) is not yet fully estab-
lished in Alzheimer’s disease.
Another neuro-degenerative disease having reciprocal rela-
tionship with cancer: the lower incidence of cancer among
patients with Huntington disease
Normal HTT protein play significant role in transport-
ing materials, chemical signaling, structural attachments
and in preventing apoptosis. It also impacts on function-
ing of several transcription factors and many genes. Cor-
tical neurons produce BDNF transcription, it enhances
neuronal survival. Huntingtin is involved in this upregu-
lation of BDNF transcription. When HTT gets mutated
in Huntington disease, this activity of HTT also disap-
pears and production of BDNF decreases. It has already
been reported that there is decreased incidence of cancer
in Huntington disease patients and this seems to be re-
lated to intrinsic biologic factors [3]. In Huntington dis-
ease, HTT protein is modified and it increases the rate
of apoptosis, also provides protection against cancer. But
this increased rated of apoptosis in Huntington disease
causes neurodegeneration. It is important to note that
BDNF, P53, increased apoptosis, transcription changes,
are also among the aspects in which cancer and Alzhei-
mer’s disease have reciprocal relationship.
Weakened anti-stress responses such as vimentin, car-
nosine, stress protein expression, HSPs and ubiquitin
Anti-stress responses gets weakened with age, this in
turn also contributes to the development of Alzheimer’s
disease such as Vimentin has decreased expression in
Alzheimer’s disease but over-expressed in Cancer,
Carbonic anhydrases are increased in Cancers while de-
creased in AD brains. HSPs are increased in cancers but
decreased in AD, SAPK downregulation occurs in cancer
for survival of cancerous cells and SAPK inhibitors can
prevent neuronal apoptosis in AD. All of these weakened
anti-stress responses also signify the inverse relationship
between Alzheimer’s disease and cancer. Carnosine that
is an anti-aging homeostatic agent, neuro-protective and
antineoplastic, its response also weakens with age, thus
contributing to the development of AD. Carnosine and
FOXO have complex relationship to both these diseases.
Vimentin has decreased expression in Alzheimer’s disease
but over-expressed in cancer
In brain tissues from several human CNS and non-
neurological disease cases, immunoreactivity of vimentin
was highly positive in subpial and ependymal cells, but
in some white matter astrocytes and in some capillaries,
it was weakly positive. Vimentin- immunoreactivity in
astrocytes, macrophages and microglia becomes in-
tensely positive in areas of brain affected by Alzheimer’s
disease, multiple sclerosis, Pick’s disease, amyotrophic
lateral sclerosis and cerebral infarction patients. But in
AD, they are found specially associated with beta amyl-
oid plaques [71]. Before there is loss of neurons in AD,
there is loss of synapsis, retraction of dendrites. Re-
sponse of neurons to this development of AD pathology
is still not properly known. In brains affected by AD,
there is localization of vimentin to dendrites and peri-
kariya of neurons. There commonly occurs co-
localization of vimentin and beta amyloid plaques in
hippocampus, cerebral cortex and in cerebellum. Even
AD affected regions of transgenic mice, when
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mechanically injured, these regions expressed vimentin.
During human embryonic development, vimentin ex-
pression occurs concurrently in relation to rapid exten-
sion of neurite. Expression of vimentin by neurons is an
evolutionarily conserved mechanism to counter damage
response which repeats a developmental pathway that
differentiating neurons use in establishing connections
in synapses and dendrites [72].
Vimentin provides protection against cellular stress
and is also involved in maintenance of cellular integrity.
It is important to note that dendrites and synaptic con-
nections are among the most affected ones in AD.
Growth of dendrites contributes to the learning and for-
mation of memories. In AD, vimentin expression that
has also been termed damage response mechanism is
limited to Astrocytes, Microglia, and Beta Amyloid
plaques, and also is not that much as in Ischemic brain
Injury. Vimentin possibly also controls other proteins, it
regulates transcription. It has multiple functions and is
able to interact with several proteins, and potentially regu-
lates several physiological functions. It contributes to
maintenance of structural integrity of cells. Several other
functions of vimentin are yet to be investigated [73].
This may point to new insights about AD. It perhaps
is due to decreased expression of factors that are re-
quired to maintain neuronal homeostasis, such as de-
creased expression of vimentin that has damage
response mechanisms that Alzheimer’s disease develops.
As a person ages, neurons have to counter stress daily
and they have mechanisms to counter this stress. The
expression of such anti-stress mechanisms continue to
decline with ongoing age and when such ongoing de-
cline in expression reaches a certain point, neuronal
damage begins to manifest clinically and AD signs and
symptoms begin to appear. Expression of Vimentin is
present in normal mesenchymal cells, neuronal precur-
sor cells, sertoli cells, and fibroblasts. This protein is
present both outside and inside the cells. Vimentin is an
Intermediate filament (IF) protein and IF proteins play
role in bringing about RNA and DNA-mediated events
inside the cell nucleus. There are various cancers in
which over-expression of vimentin is present including
breast cancer, prostate cancer, lung cancer, CNS tumors,
gastrointestinal tumors, malignant melanoma and other
cancer types. This over-expression co-relates with upreg-
ulated growth of tumors and invasion [74].
Carbonic anhydrases are increased in cancers while
decreased in AD brains
In AD brains, activity of carbonic anhydrase (CA) is de-
creases, and when carbonic anhydrase activators are ad-
ministered, this contributes to improvement in learning
in animals [75]. CA is activated by carnosine. Carbonic
anhydrases are increased in Cancer [76].
Carnosine: an antiaging homeostatic agent that is neuro-
protective and anti-neoplastic
Functioning and levels of carnosine deteriorates with
age, and this contributes to AD and cancer development.
Carnosine is neuroprotective, and also anti-proliferative.
As both diseases are considered age-related, it is also
anti- aging. And it has been found to be pro-apoptosis
and anti–apoptosis as well. Beta amyloid toxicity can be
suppressed by carnosine; a homeostatic, pluripotent, nat-
urally occurring agent. It also scavenges reactive alde-
hydes and hydroxyl radicals, suppresses protein
glycation, and inhibits the production of ROS. High
levels of both zinc and carnosine are present in olfactory
lobe. In AD, one of the early symptoms is the decline in
olfactory function, and olfactory tissues are damaged by
oxidative stress. Aging causes decline in the levels of
homocarnosine in human CSF. In NFTs of AD brains,
there is presence of gamma-glutamyl-epsilon-amino;
protein cross-links. From biological tissue, gamma-
glutamyl-carnosine has already been isolated. It is
important to note that in cultured human fibroblasts,
vimentin expression is stimulated by carnosine. There
is also co-expression of vimentin with protease
oxidized-protein-hydrolase. Carnosine is also involved
in stimulating proteolysis in senescent cultured fibro-
blasts and in cultured myocytes [75]. Further explor-
ation of carnosine and other such agents is needed,
as they may potentially play role in development of
new therapies towards neurodegenerative disorders in-
cluding AD. Carnosine decreases growth of tumors
and lowers the quantity of mitotic cells in them; this
has been shown in animals. Carnosine negatively im-
pacts the proliferation. It has high potential to halt
the growth of malignant cells [77].
Carnosine has other significant beneficial effects too,
such as prevents dysfunction of testicles caused by
gamma-irradiation. It does this prevention because it
has anti-apoptotic effect and it also lowers ROS. Carno-
sine also maintains normal levels of glutathione when
the brain has suffered ischemia. It also provides neuro-
protection [78].
Role of HSPs and inverse relationship between AD and
cancer
Carnosine upregulates the gene expression of stress pro-
tein and synthesis of nitric oxide contributes to elimin-
ate altered proteins proteasomally [79]. Synthesis of
‘stress proteins’ becomes elevated whenever cell is in
conditions of stress. Stress proteins are also called heat
shock proteins (HSPs), they have significant role in nor-
mal and injured cells. HSP expression increases in re-
sponse to stress vectors including ischemia and high
temperature [80]. This increase in gene expression of
HSP is induced by heat shock factor (HSF). HSF 1
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increases and maintains the gene expression of Hsp70. It
is already known that specific neuronal structures such
as synapses and axons also harbor HSPs that may be
misregulated during the Alzheimer’s disease processes.
HSF 1 has the powerful capacity to modify carcinogen-
esis. HSF1 is involved in promoting metastasis and sur-
vival in cancer cells. Inhibition of HSF1 impairs
mitogenic (MAPK) signaling and contributes to inducing
apoptosis in cancer cells [81]. It may also be possible
that some of the HSPs may be upregulated to counter
Alzheimer’s related damage, and this needs to be further
investigated.
Ubiquitin levels are decreased in Alzheimer’s disease and
increased in cancer, also signify the inverse relationship
between Alzheimer’s disease and cancer
Ubiquitin is involved in marking protein for degradation.
It also has properties of heat shock proteins (HSPs). In
cancer cells, there is high expression of HSPs, and it
contributes significantly to their survival. Gene expres-
sion is also regulated by ubiquitination of histones. Ubi-
quitination is also significantly involved in regulating
transcription factors p53 and Myc [82]. When amyloid
precursor protein (APP) becomes malformed, it contrib-
utes to AD development, but this malformation is de-
creased when higher levels of ubiquitin are present in
the brains and lower levels increase the malformation of
APP [83]. Ubiquitin also contribute to neuroprotection
against ischemic injuries [84].
It’s important to note that carnosine upregulates
stress proteins, and ubiquitin has also effects of stress
proteins and they can modulate transcription and
transcription factors including Myc and p53. Process
of transcription is modulated by all these effects.
Increased levels of ubiquitin have neuroprotective
affects.
SAPK downregulation occurs in cancer for survival of
cancerous cells and SAPK upregulation occurs in AD, also
signifying the inverse relationship between cancer and
Alzheimer’s disease
In AD, neuronal apoptosis is mediated by oxidative
stress induced by beta amyloid plaques. Stress-
activated protein kinases (SAPK) regulate mitochon-
drial pathways including Bcl2 and p53, which paly
roles in apoptosis. SAPK upregulates p53 levels, but
MAPK, p38 and JNKs are capable of specifically inhi-
biting SAPK and apoptosis [31]. When cells become
cancerous, stress signaling is induced and levels of
SAPKs and ROS are increased to contribute to apop-
tosis. But when tumors become advanced, this death
signaling is down-regulated [85].
Normal functioning of cell mechanisms deteriorates with
increasing old age, such as decreased regulation of signal
transduction and gene expression occurs in AD brains
Vitamin E is a redox sensor and regulates gene expres-
sion and signal transduction. It has also been shown to
decrease and slow the cognitive decline in AD patients
when given in high doses [86].
FOXO helps in cell survival and p53 is involved in cell
death; their relation to AD
Aging weakens the functioning of FOXO and thus this
contributes to AD development. Ultimately this favors
p53 upregulation, resulting in increased neuronal death
and further acceleration of Alzheimer’s disease. Aging
increases the risk of AD. FOXO is involved in counter-
ing stress, maintenance of neural stem cells and also
contributes to longevity. It also play important role in
cellular proliferation, metabolism and tolerance of stress.
Ubiquitination, phosphorylation and acetylation and
other post-translational modifications are involved in
tightly regulating the activity of FOXO. Many enzymes
that contribute to post-translational modifications are
shared between p53 and FOXO, and they affect both in
opposing manner. This may underlie a balance between
lifespan and disease [87].
The following measures are possibly the
‘Countermeasures or compensatory mechanisms by AD
affected neurons’ as last attempts for survival which may
be protective for certain time such as Tau, Beta Amyloid,
S100 – or can speed up AD in the Alzheimer’s disease
microenvironment via C-ABL activation, GSK3, neuro-
inflammation
Cellular pathways involved in growth, proliferation, de-
velopment, gene expression and survival, are utilized as
compensatory mechanisms by AD neurons, and this
helps in survival for a limited time as the degenerating
environment becomes more toxic, then they ultimately
contribute to further AD progression. Some of the key
pathways that may be playing compensatory roles have
been pointed in this study. Roles of all these pathways as
compensatory mechanisms or countermeasures have
been proposed in the light of scientific literature. And all
these roles need to be further investigated also via using
AD animal models.
GSK3 involved in neurodevelopment and it also appears in
Alzheimer’s disease, but in AD the microenvironment is
neurotoxic so ultimately it speeds up AD
GSK3 is involved in pathogenesis of AD. GSK3b in-
volved in proliferation, differentiation, motility and sur-
vival during embryogenesis. Mdm2 is responsible for
degrading p53 proteasomally, in physiologic conditions.
But in times of cellular stress, there is stabilization of
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p53 and a complex formation with GSK3β. This causes
hyper-phosphorylation of tau, enhanced accumulation of
beta amyloid plaques and upregulation of GSK3β. P53 is
upregulated and its proteasomal degradation is inhibited
in the presence of beta amyloid plaques. It is also con-
sidered that phosphorylated p53 and GSK3β work to-
gether in the development of AD. NFTS and beta
amyloid plaques are considered among the principal
components of AD. It is assumed that NFTs and plaques
may be responsible for neuro-toxicity or they may actu-
ally be a mechanism to provide neuro-protection [5].
Glycogen synthase kinase 3 (GSK3) is involved in neuro-
developmental fundamental processes, and if this signal-
ing is disrupted, it then contributes to cause neurodeve-
lopmental disorders. GSK3 signaling contributes to
development of neurons, their polarization and growth
of axons, when brain is in the phase of development. It
is involved in mediating multiple cellular processes and
impacts several signaling molecules [88, 89].
Physiologically, GSK3 contributes to maintenance of
cell structure, gene expression, apoptosis and metabol-
ism. GSK3 signaling is extremely important in neural de-
velopment and perhaps in order to repair the damage
and to protect the cells from AD neuro-degeneration,
this protein appears in AD brains but micro-
environment is now quite different as compared to the
time of embryogenesis, and in AD p53 gets stabilized
forming a complex with GSK3β and contributes to neur-
onal death, ultimately speeding up AD.
C-Abl is involved in neurodevelopment and is turned up in
CML but it is also present in AD brains, not halting AD
C-Abl protein is a tyrosine kinase. It plays significant
roles in developmental pathways including cellular pro-
liferation, adhesion and differentiation. C-Abl turns on
the cell cycle in the brain of adults, this damages the
cells and cause phosphorylation of tau [90]. C-Abl is also
present in beta amyloid plaques and NFTs in AD brains.
It is significant to point out that this protein is upregu-
lated in B cells in chronic myeloid leukemia (CML). It is
hypothesized here that as Alzheimer’s disease halts
neurogenesis, so alternatively C-Abl here is utilized to
serve the purpose turn on the cell cycle but in adult
brain it damages the cells and further accelerates the
AD, as the cell environment and surrounding micro-
environment is neurotoxic.
Neuro-inflammation, S100B, Down syndrome and
Alzheimer’s disease
Down syndrome halts growth and also causes early
Alzheimer’s disease. Among defects Trisomy 21 causes
premature aging and mental retardation. It is also
considered possible that initial events in AD pathogen-
esis are driven by cytokines, because there occurs
inflammation of neurons, glial cells dramatically multiply
and over-express IL-1 and S100B in the brains of down
syndrome patients [91]. Interleukin (IL)-6, a marker for
neuro-inflammation, is found in brains of AD and DS. IL-
6 is involved in modulation of growth and differentiation
in various malignancies. Estrogen, whose role has previ-
ously been mentioned as anti- AD, is inhibitor of IL6.
Physiologically, S100B regulates proliferation of cells
and axons, differentiation, neurite extension, astrocytosis
and other cellular processes. It also functions as a survival
signal and neurotrophic factor. It is important to note that
S100B and its receptor is upregulated in AD [92].
Down syndrome cause early onset AD, both the
Trisomy 21 and AD have defective growth, proliferation,
maintenance and survival responses in many aspects. It
may be hypothesized that as patient’s brain cells need
mechanisms for proper regulation of growth, survival
and maintenance of brain cells, but Trisomy 21 tends to
halt these responses. In order to compensate this effect
of Trisomy 21; IL- 1, IL -6 and S100B are utilized to
serve this purpose. IL – 1 and IL - 6 also results in
neuro-inflammation and accumulation of plaques in
neurotoxic micro-environment of AD, ultimately speed-
ing up AD.
S100B is utilized for neural growth and maintenance
but is insufficient to stop progression of AD damage.
SPs, NFTs and GVDs are also found in normal aging brains
Growth, proliferation, survival and maintenance mecha-
nisms are impaired in AD brains, it is perhaps because
of this reason that growth of dendrites is also impaired
compared to healthy individuals. SPs and NFTs both
have been found in healthy brains. They also have roles
in developmental processes, gene expression and sur-
vival. Kinases are known to play roles in cell signaling
and carcinogenesis, and Kinases such as MARK 3-4 have
also been found in GVDs. The presence of SPs, NFTs
and GVDs in AD brains may actually be a compensatory
response to aid in preventing AD related damage to
brain structures but as the micro-environment becomes
neurotoxic, they ultimately speed up AD.
Tau Changes in healthy persons are involved in regu-
lating developmental processes and gene expression
[93]. Many studies have already suggested that phos-
phorylation of tau is significant for generation of neu-
rons in hippocampal region [94]; some neurons
containing NFTs survive for decades and a great number
of neurons are already lost before NFTs appear. There is
also possibility that NFTs are not directly related to de-
generation of neurons as they have already been ob-
served in seemingly healthy people. Therefore, it has
already been suspected and proposed that NFTs form as
a compensatory mechanism after oxidative damage, and
this damage results in activation of multiple kinases
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which led to tau phosphorylation. This formation of
NFTs prolongs the normal functioning of neurons for a
certain period of time. The role of micro-environment in
normal functioning, development and maintenance of
tissues is very significant. Beta amyloid plaques may
impact AD- associated genes transcriptionally. Beta-
Amyloid also may be part of mechanism to counter
aging related neuronal troubles, as SPs are also found in
normal aging brain. GSK3beta contributes to develop-
ment of AD and its role has already been mentioned. It
interacts with beta amyloid plaques, NFTs, presenilin
and with other AD related proteins. APOE4 increases
the risk of AD, only the risk not the AD itself [5].
Granulovascular Degeneration Bodies (GVDS) are
rarely seen before age 65, but become increasingly com-
mon with age. GVDs contain increased MARK 4 and
then MARK 3 in AD patients compared to non-
demented elderly. Microtubule affinity regulating kinase
(MARK) phosphorylates Ser262 site on tau, this phos-
phorylation is correlated with the expressions of MARK3
and MARK4 in GVDs in AD brains, and detaches tau
from microtubules. This detached tau then becomes
available for more phosphorylation [95]. Drug which
modulated gamma secretase and also blocked complex
of PS1 to avoid production of beta amyloid plaques, failed
fully to halt AD [96]. If beta amyloid plaques had been the
key culprit behind AD, then preventing Aβ 1–42 produc-
tion would have already been successful in preventing
cognitive decline in AD patients.
It has already been discovered on the basis of post
mortem studies, beta amyloid plaques may appear in
healthy elderly brains and may be absent even in highly
progressed AD cases. Hallmarks of Ad are also in76% of
normal persons.
Physiologic functions of Aβ include kinase activation,
ion channel formation, cholesterol transport regulation
and neuro-protection against oxidative stress to some
extent. APP and Tau are involved in brain development,
gene expression but when are impaired, they contribute
to Alzheimer’s disease progression. APP plays significant
roles in proper neuronal functioning and in brain devel-
opmental pathways, but in AD it changes to βAP. And
this change into βAP may be a compensatory response
to counter AD-related damage.
Tau a microtubule associated protein: role, and its relation
to Alzheimer’s disease and cancer
Hyperphosphorylated tau as NFTs accumulates in cere-
bral cortex and hippocampal regions of the brain in AD
patients. When tau becomes hyperphosphorylated, it
then may become unable to bind properly to microtu-
bules and ultimately resulting in their collapse. Roles of
microtubules are well known in developmental processes
and in regulation of gene expression. Microtubules and
associated proteins such as MAPs play very significant
role in the development of CNS. They and tau are
present in high quantities during the development of
brain and are also involved in crosslinking microtubules
inside the neurons. Tau works in relation to tubulin in
cross-liking process [97]. AD is associated with accumu-
lation of beta amyloid plaques and tau hyperphosphory-
lation. Generation of new neurons becomes impaired in
AD. It is important to point out here that phosphoryl-
ation of tau significantly contribute to neurogenesis in
hippocampal region of brain [98]. Cytoskeleton of cells
including microtubules regulate expression of genes,
support intracellular structures and transport, contribute
to signal transduction and to generation of some growth
factors including connective tissue growth factor.
It is significant to note that antineoplastic drugs acting
on microtubules, harm the cell survival and proliferation
and ultimately led to cell death of cancer cells [99–101].
This signifies the growth maintaining and promoting role
of microtubules and tau. With increasing age, this role
also deteriorates and increased hyper-phosphorylation of
tau takes place. Tau protein is involved in developmental
processes, differential gene expression and growth factors
production, and tau phosphorylation is also involved in
neurogenesis. Its accumulation as NFTs in AD brains may
actually be a compensatory response by neurons to pro-
long their survival in AD brains, but ultimately the degen-
erating environment makes this response insufficient and
contributes to AD progression. Many processes that are
involved in growth, development, and neoplasia are
down-regulated or deteriorate in AD, and pointing this
out is one of the aims of this study.
Discussion
This research article attempts to investigate what causes
and makes the Alzheimer’s disease process begin. Under-
standing the relationship between cancer and AD, in
terms of cellular pathways and molecular mechanisms
will help to understand better the pathogenesis and fac-
tors behind Alzheimer’s disease. This study also investi-
gates how age related changes in growth, cell survival
responses, maintenance mechanisms, anti-stress re-
sponses, contribute to development and progression of
Alzheimer’s disease.
In the light of scientific literature, this research paper
also points to possible mechanisms and pathways that
may be playing role or contributing to Alzheimer’s dis-
ease pathogenesis. But these possible mechanisms and
pathways need to be further investigated. Cancer and
Alzheimer’s disease have inverse relationship and all the
factors that are inversely related, also other factors and
changes that lead or contribute to the development of
AD may also be new potential tools for diagnostic test-
ing especially for Alzheimer’s disease and also in
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designing new potential interventions and treatments for
both diseases but especially for Alzheimer’s disease. Un-
derstanding both these age-related diseases may also
provide deep insights into the biology of aging. This
study may also potentially provide new insights into
biology of aging. This research article may help answer-
ing the questions. Such as, why does AD affect some
aged people but not everyone? How genes contributing
to AD interact with environmental and lifestyle factors
and other genes, and how this impacts the risk of AD
development? Who are more likely to develop AD?
All those factors that contribute to growth and prolif-
eration are increased in Cancer but decreased in
Alzheimer’s disease. This simply does not mean that
every cellular or molecular pathway should have inverse
relationship; there are so many pathways that are com-
mon and even operate similarly in many cell types, and
are not altered by disease processes. Some of the key
pathways that may be playing compensatory roles have
been pointed in this study. It is important to note that
cancer is not a single disease; there are multiple types of
cancers. Roles of all the pathways as compensatory
mechanisms or countermeasures have been proposed in
the light of scientific literature. And all these roles need
to be further investigated also via using AD animal
models. It also suggests some hypothesis in the light of
scientific literature and also highlights the changes
occurring at cellular and molecular level esp. in AD.
This research study has taken a different approach and
aims to further advance the understanding of AD devel-
opment and progression. This paper cites evidence in
support of this study from already well-established and
published research literature. Further research and
experimental studies at molecular, genetic, epigenetic
and cellular levels, will reveal deeper details about the
findings presented in this study. This may take our
understanding of Alzheimer’s disease, Cancer and Aging
biology to greatest depths. Experiments should also be
devised so as to investigate which factors greatly contrib-
ute to AD or are causative directly or indirectly. Investi-
gating aging in greater depths will also lead to better
understanding of age-related diseases such as
Alzheimer’s disease.
Conclusions
It’s the age-related cellular and genomic changes that
when becomes pathologic to such an extent that age-
related diseases such as Alzheimer’s disease and cancer
appear. When mechanisms involved in physiologic
growth, development, maintenance, proper gene expres-
sion are impaired, then they result in AD. Aging greatly
contributes to these impairments. Alzheimer’s disease
and cancer, both are age related diseases, one is degen-
erative and other is over-proliferative. Many factors that
are upregulated in any Cancer to sustain growth and
survival are downregulated in Alzheimer’s disease con-
tributing to neuro-degeneration.
There is inverse relationship between Cancer and
Alzheimer’s disease in aspects such as P53, estrogen,
neurotrophins and growth factors, growth and prolifera-
tion, cAMP, EGFR, Bcl-2, apoptosis pathways, IGF-1,
HSV, TDP-43, Alzheimer’s risk decreases from apoE4 to
E3 to E2 but growth and survival improves respectively,
notch signals and presenilins, NCAM, TNF alpha, PI3K/
AKT/MTOR pathway, telomerase, ROS, ACE levels.
Anti-stress responses gets weakened with age, this in
turn also contributes to the development of Alzheimer’s
disease such as Vimentin, Carbonic anhydrases, HSPs,
SAPK. All of these weakened anti-stress responses also
signify the inverse relationship between Alzheimer’s
disease and cancer.
Carnosine that is an anti-aging homeostatic agent,
neuro-protective and antineoplastic, its response also
weakens with age, thus contributing to the development
of AD. Carnosine and FOXO have complex relationship
to both these diseases.
There are ‘Countermeasures or compensatory mecha-
nisms by AD affected neurons’ as last attempts for sur-
vival which may be protective for certain time such as
Tau, Beta Amyloid, S100 or can speed up AD in the
Alzheimer’s disease microenvironment via C-ABL acti-
vation, GSK3, neuro-inflammation.
Cellular pathways involved in growth, proliferation,
development, gene expression and survival, are utilized
as compensatory mechanisms by AD neurons, and this
helps in survival for a limited time as the degenerating
environment becomes more toxic, then they ultimately
contribute to further AD progression.
This study is important as it signifies inverse relation-
ship between AD and cancer via elaborating cellular and
molecular pathways that are responsible for this rela-
tionship. It also points to other significant factors and
their roles in AD development and progression. It signi-
fies how deteriorating growth and survival mechanisms
contribute to AD, providing new insights into AD
pathogenesis.
Study design
The etiology of Alzheimer’s disease is yet not properly
known. This research study finds evidence from already
published research literature to find factors and changes
that lead to the development of Alzheimer’s disease and
finds the inverse relationship between Cancer and
Alzheimer’s disease.
It investigates the cellular pathways having roles in
cancers, development, aging, cell survival, growth and
proliferation, and also contributing to Alzheimer’s
disease (Additional file 1).
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